Risk Score for Outcome After Allogeneic Hematopoietic Stem Cell Transplantation A Retrospective Analysis

BACKGROUND: It was investigated whether the European Group for Blood and Marrow Transplantation risk score, previously established for chronic myeloid leukemia, could be used to predict outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for hematological disease in general. METH...

Descripción completa

Detalles Bibliográficos
Autores: Gratwohl, A, Stern, M, Brand, R, Apperley, J, Baldomero, H, de Witte, T, Dini, G, Rocha, V, Passweg, J, Sureda, A, Tichelli, A, Niederwieser, D
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2009
País:España
Institución:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p13114
Acceso en línea:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=13114
Access Level:acceso abierto
Palabra clave:hematopoietic stem cell transplantation
outcome
risk score
allogeneic
hematological malignancy
leukemia
id ES_7c92aeefa2b91cfe6b5cfda5e431f6b2
oai_identifier_str oai:iibsantpau.fundanetsuite.com:p13114
network_acronym_str ES
network_name_str España
repository_id_str
spelling Risk Score for Outcome After Allogeneic Hematopoietic Stem Cell Transplantation A Retrospective AnalysisGratwohl, AStern, MBrand, RApperley, JBaldomero, Hde Witte, TDini, GRocha, VPassweg, JSureda, ATichelli, ANiederwieser, Dhematopoietic stem cell transplantationoutcomerisk scoreallogeneichematological malignancyleukemiaBACKGROUND: It was investigated whether the European Group for Blood and Marrow Transplantation risk score, previously established for chronic myeloid leukemia, could be used to predict outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for hematological disease in general. METHODS: Age of patient, disease stage, time interval from diagnosis to transplant, donor type, and donor-recipient sex combination were used to establish a score from 0 to 7 points. Its validity was tested in 56,505 patients, 33,113 (58%) male, 23,392 female, median age 33 years (range, 0.5-77 years), with an allogeneic HSCT for a hematological disorder between 1980 and 2005. RESULTS: Survival probability at 5 years decreased from 71% (95% confidence interval [CI], 69%-73%) for risk score 0 for the whole cohort (75%, 95% Cl, 72%-78% for the most recent time cohort) to 24% (95% Cl, 21%-27% for risk score 6 and 7; 25%, 95% Cl, 22%-29% most recent cohort). Transplant-related mortality increased from 15% (95% Cl, 14%-17%) for risk score O (11%, 95% Cl, 9%-13%, most recent cohort) to 47% with risk score 6 and 7 (95% Cl, 44%-50%) for the whole cohort (45%, 95% Cl, 42%-48%, most recent cohort). The risk score was predictive in all disease categories, over all time periods, and was not altered by transplant techniques. CONCLUSIONS: Five well-defined pretransplant patient and donor characteristics give a reasonable risk estimate of allogeneic HSCT. This risk score can provide a basis for the decision between transplant and nontransplant strategies. Cancer 2009;115:4715-26. (C) 2009 American Cancer Society.WILEY2009info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=13114CANCERISSN: 0008543XISSNe: 10970142reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pauinstname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)Inglésinfo:eu-repo/semantics/openAccessoai:iibsantpau.fundanetsuite.com:p131142026-06-14T12:41:47Z
dc.title.none.fl_str_mv Risk Score for Outcome After Allogeneic Hematopoietic Stem Cell Transplantation A Retrospective Analysis
title Risk Score for Outcome After Allogeneic Hematopoietic Stem Cell Transplantation A Retrospective Analysis
spellingShingle Risk Score for Outcome After Allogeneic Hematopoietic Stem Cell Transplantation A Retrospective Analysis
Gratwohl, A
hematopoietic stem cell transplantation
outcome
risk score
allogeneic
hematological malignancy
leukemia
title_short Risk Score for Outcome After Allogeneic Hematopoietic Stem Cell Transplantation A Retrospective Analysis
title_full Risk Score for Outcome After Allogeneic Hematopoietic Stem Cell Transplantation A Retrospective Analysis
title_fullStr Risk Score for Outcome After Allogeneic Hematopoietic Stem Cell Transplantation A Retrospective Analysis
title_full_unstemmed Risk Score for Outcome After Allogeneic Hematopoietic Stem Cell Transplantation A Retrospective Analysis
title_sort Risk Score for Outcome After Allogeneic Hematopoietic Stem Cell Transplantation A Retrospective Analysis
dc.creator.none.fl_str_mv Gratwohl, A
Stern, M
Brand, R
Apperley, J
Baldomero, H
de Witte, T
Dini, G
Rocha, V
Passweg, J
Sureda, A
Tichelli, A
Niederwieser, D
author Gratwohl, A
author_facet Gratwohl, A
Stern, M
Brand, R
Apperley, J
Baldomero, H
de Witte, T
Dini, G
Rocha, V
Passweg, J
Sureda, A
Tichelli, A
Niederwieser, D
author_role author
author2 Stern, M
Brand, R
Apperley, J
Baldomero, H
de Witte, T
Dini, G
Rocha, V
Passweg, J
Sureda, A
Tichelli, A
Niederwieser, D
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv hematopoietic stem cell transplantation
outcome
risk score
allogeneic
hematological malignancy
leukemia
topic hematopoietic stem cell transplantation
outcome
risk score
allogeneic
hematological malignancy
leukemia
description BACKGROUND: It was investigated whether the European Group for Blood and Marrow Transplantation risk score, previously established for chronic myeloid leukemia, could be used to predict outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for hematological disease in general. METHODS: Age of patient, disease stage, time interval from diagnosis to transplant, donor type, and donor-recipient sex combination were used to establish a score from 0 to 7 points. Its validity was tested in 56,505 patients, 33,113 (58%) male, 23,392 female, median age 33 years (range, 0.5-77 years), with an allogeneic HSCT for a hematological disorder between 1980 and 2005. RESULTS: Survival probability at 5 years decreased from 71% (95% confidence interval [CI], 69%-73%) for risk score 0 for the whole cohort (75%, 95% Cl, 72%-78% for the most recent time cohort) to 24% (95% Cl, 21%-27% for risk score 6 and 7; 25%, 95% Cl, 22%-29% most recent cohort). Transplant-related mortality increased from 15% (95% Cl, 14%-17%) for risk score O (11%, 95% Cl, 9%-13%, most recent cohort) to 47% with risk score 6 and 7 (95% Cl, 44%-50%) for the whole cohort (45%, 95% Cl, 42%-48%, most recent cohort). The risk score was predictive in all disease categories, over all time periods, and was not altered by transplant techniques. CONCLUSIONS: Five well-defined pretransplant patient and donor characteristics give a reasonable risk estimate of allogeneic HSCT. This risk score can provide a basis for the decision between transplant and nontransplant strategies. Cancer 2009;115:4715-26. (C) 2009 American Cancer Society.
publishDate 2009
dc.date.none.fl_str_mv 2009
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=13114
url https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=13114
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv WILEY
publisher.none.fl_str_mv WILEY
dc.source.none.fl_str_mv CANCER
ISSN: 0008543X
ISSNe: 10970142
reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
instname_str Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
reponame_str r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
collection r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869411600061956096
score 15.811543

Similares en LA Referencia